Very low dose rituximab may not sustainably kill B-cells: Trial
Very low doses of rituximab rapidly reduced blood levels of disease-driving B-cells in people with cold agglutinin disease (CAD) and other forms of autoimmune hemolytic anemia (AIHA), but this suppression was not consistently sustained over time. Those are the findings of a small pilot Phase 2 clinical…